Compare Stocks: APDN, QNCX, ESLA, and GNTA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APDN Applied DNA Sciences	$6.15 +44.0%	$4.65	$0.29 ▼ $7.15	$7.94M	0.15	516,804 shs	2.76 million shs
ESLA Estrella Immunopharma	$0.72 -0.2%	$0.88	$0.68 ▼ $3.15	$31.12M	0.88	39,046 shs	9,010 shs
GNTA Genenta Science	$1.30	$1.59	$0.55 ▼ $10.00	$30.67M	0.77	61,985 shs	26,104 shs
QNCX Quince Therapeutics	$34.04 +5.0%	$21.01	$15.10 ▼ $909.98	$34.62M	1.36	35,861 shs	26,046 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APDN Applied DNA Sciences	0.00%	0.00%	0.00%	0.00%	+46.06%
ESLA Estrella Immunopharma	0.00%	+0.08%	-2.55%	-34.85%	-14.89%
GNTA Genenta Science	0.00%	0.00%	-9.72%	+107.01%	-59.38%
QNCX Quince Therapeutics	0.00%	+12.72%	+82.32%	+48.00%	-90.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APDN Applied DNA Sciences	$6.15 +44.0%	$4.65	$0.29 ▼ $7.15	$7.94M	0.15	516,804 shs	2.76 million shs
ESLA Estrella Immunopharma	$0.72 -0.2%	$0.88	$0.68 ▼ $3.15	$31.12M	0.88	39,046 shs	9,010 shs
GNTA Genenta Science	$1.30	$1.59	$0.55 ▼ $10.00	$30.67M	0.77	61,985 shs	26,104 shs
QNCX Quince Therapeutics	$34.04 +5.0%	$21.01	$15.10 ▼ $909.98	$34.62M	1.36	35,861 shs	26,046 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APDN Applied DNA Sciences	0.00%	0.00%	0.00%	0.00%	+46.06%
ESLA Estrella Immunopharma	0.00%	+0.08%	-2.55%	-34.85%	-14.89%
GNTA Genenta Science	0.00%	0.00%	-9.72%	+107.01%	-59.38%
QNCX Quince Therapeutics	0.00%	+12.72%	+82.32%	+48.00%	-90.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APDN Applied DNA Sciences	1.00	Sell	N/A	N/A
ESLA Estrella Immunopharma	2.00	Hold	$8.00	1,006.19% Upside
GNTA Genenta Science	1.00	Sell	N/A	N/A
QNCX Quince Therapeutics	2.27	Hold	$310.50	812.16% Upside

Current Analyst Ratings Breakdown

Latest APDN, QNCX, ESLA, and GNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/29/2026	QNCX Quince Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$82.00
7/21/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/10/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	QNCX Quince Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	QNCX Quince Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/24/2026	QNCX Quince Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$80.00

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APDN Applied DNA Sciences	$3.74M	2.12	N/A	N/A	$215.25 per share	0.03
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	($0.27) per share	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	$1.29 per share	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APDN Applied DNA Sciences	-$6.99M	-$923.81	N/A	N/A	N/A	-399.91%	-136.17%	-101.95%	N/A
ESLA Estrella Immunopharma	-$13.06M	-$0.24	N/A	N/A	N/A	N/A	N/A	-289.98%	9/2/2026 (Estimated)
GNTA Genenta Science	-$7.39M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)
QNCX Quince Therapeutics	-$83.98M	-$156.71	N/A	N/A	N/A	N/A	N/A	-67.99%	N/A

Latest APDN, QNCX, ESLA, and GNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	N/A	ESLA Estrella Immunopharma	-$0.09	N/A	N/A	N/A	N/A	N/A
9/2/2026	N/A	GNTA Genenta Science	-$0.2741	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	-$12.31	+$15.71	-$12.31	N/A	N/A
8/13/2026	Q2 2026	ESLA Estrella Immunopharma	-$0.09	-$0.05	+$0.04	-$0.05	N/A	N/A
5/16/2026	Q1 2026	ESLA Estrella Immunopharma	-$0.0840	-$0.05	+$0.0340	-$0.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APDN Applied DNA Sciences	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APDN Applied DNA Sciences	N/A	2.76	2.60
ESLA Estrella Immunopharma	N/A	0.24	0.24
GNTA Genenta Science	0.35	14.16	14.16
QNCX Quince Therapeutics	N/A	2.92	2.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APDN Applied DNA Sciences	22.22%
ESLA Estrella Immunopharma	0.35%
GNTA Genenta Science	15.13%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
APDN Applied DNA Sciences	0.17%
ESLA Estrella Immunopharma	5.80%
GNTA Genenta Science	28.99%
QNCX Quince Therapeutics	7.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APDN Applied DNA Sciences	70	1.29 million	1.29 million	Optionable
ESLA Estrella Immunopharma	N/A	43.03 million	40.54 million	Not Optionable
GNTA Genenta Science	7	23.59 million	16.75 million	Not Optionable
QNCX Quince Therapeutics	60	1.02 million	945,000	Optionable

APDN, QNCX, ESLA, and GNTA Headlines

Recent News About These Companies

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

August 14 at 8:00 AM | globenewswire.com

Quince Therapeutics (QNCX) Projected to Announce Earnings on Tuesday

August 9, 2026 | americanbankingnews.com

Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Rating of "Hold" from Brokerages

August 5, 2026 | americanbankingnews.com

Quince Therapeutics

July 6, 2026 | fool.com

Quince Therapeutics Stock Short Interest Report | NASDAQ:QNCX | Benzinga

July 2, 2026 | benzinga.com

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

June 30, 2026 | globenewswire.com

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

June 11, 2026 | seekingalpha.com

Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy

June 2, 2026 | insidermonkey.com

Quince Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk

May 24, 2026 | theglobeandmail.com

Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript

May 18, 2026 | seekingalpha.com

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026 | globenewswire.com

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026 | globenewswire.com

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

May 18, 2026 | globenewswire.com

Quince Therapeutics (QNCX) price target increased by 100.00% to 81.60

May 15, 2026 | msn.com

Quince Therapeutics (QNCX) price target increased by 900.00% to 40.80

April 28, 2026 | msn.com

Quince Therapeutics Delays Annual 10-K Filing

April 27, 2026 | theglobeandmail.com

Quince Therapeutics settles $16.4M debt with $5.5M payment

March 30, 2026 | msn.com

Why did QNCX stock surge 40% in pre-market today?

March 30, 2026 | msn.com

Quince Therapeutics Settles Approximately $16.4 Million of Debt

March 30, 2026 | businesswire.com

Bankruptcy threat looms as Quince runs out of options

February 13, 2026 | pharmaphorum.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

APDN, QNCX, ESLA, and GNTA Company Descriptions

Applied DNA Sciences NASDAQ:APDN

Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

Estrella Immunopharma NASDAQ:ESLA

$0.72 0.00 (-0.19%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.74 +0.02 (+2.18%)

As of 08/14/2026 07:52 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Genenta Science NASDAQ:GNTA

$1.30 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.30 +0.00 (+0.38%)

As of 08/14/2026 07:27 PM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Quince Therapeutics NASDAQ:QNCX

$34.04 +1.63 (+5.03%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$33.60 -0.44 (-1.29%)

As of 08/14/2026 07:56 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APDN, QNCX, ESLA, and GNTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APDN, QNCX, ESLA, and GNTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APDN, QNCX, ESLA, and GNTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

APDN, QNCX, ESLA, and GNTA Company Descriptions

Applied DNA Sciences NASDAQ:APDN

Estrella Immunopharma NASDAQ:ESLA

Genenta Science NASDAQ:GNTA

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APDN, QNCX, ESLA, and GNTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APDN, QNCX, ESLA, and GNTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APDN, QNCX, ESLA, and GNTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

APDN, QNCX, ESLA, and GNTA Company Descriptions

Applied DNA Sciences NASDAQ:APDN

Estrella Immunopharma NASDAQ:ESLA

Genenta Science NASDAQ:GNTA

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools